Ovid Therapeutics (OVID) - 2024 Q1 - Quarterly Results

Ovid pipeline programs are advancing on track. Multiple data and regulatory milestones are expected before year-end. These include: • Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome; topline data are anticipated in Takeda's H1 2024 fiscal year • A Phase 1, double-blind, multiple-ascending dose trial evaluating OV888 (GV101) is complete; topline safety data are expected in H1 2024 • Ovid expects to initiate a Phase 2 clinical program ...